摘要
目的:探讨二甲双胍对精神分裂症肥胖患者的体重及糖脂代谢的影响。方法:将66例精神分裂症肥胖患者随机分成研究组和对照组各33例,研究组给予二甲双胍片0.75g/d,对照组给予安慰剂治疗,疗程6个月。于治疗前及治疗6个月末测定空腹血糖(FBG)、胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白(HDL)及低密度脂蛋白(LDL),测量身高和体重,计算体重指数(BMI)。结果:治疗6个月末两组比较,在BMI、FBG、TC、HDL、LDL 5个指标上差异有统计学意义(t=2.54,6.56,7.03,3.86,3.86;P均<0.05),而TG水平差异无统计学意义。结论:二甲双胍能有效改善精神分裂症肥胖患者的体重增加及糖脂代谢紊乱,值得临床应用。
Objective：To explore the effects of metformin on weight,glucose and lipid metabolism of s chizophrenia patients with obesity.Methods：66 subjects with obesity were randomly divided into two groups（study group and control group）.The study group（33 subjects） received metformin 0.75 g / day treatment for 6 months and the control group（33 subjects） received placebo treatment for 6 months.The fasting blood sugar（FBS）,cholesterol（TC）,triglyceride（TG）,high density lipoprotein（HDL）,low density lipoprotein（LDL）,height,weight and body mass index（BMI） were measured at baseline and at the end of 6 months.Results：There were significant differences on BMI,FBS,HDL,LDL at the end of 6 months between the study group and the control group（t = 2.54,6.56,7.03,3.86,3.86; all P〈0.05）,but no differences on TG.Conclusion：Metformin can improve the weight gain and the disorder of glucose and lipid metabolism of schizophrenia patients with obesity effectively.
出处
《中国健康心理学杂志》
2015年第5期661-663,共3页
China Journal of Health Psychology
基金
荆州市科技发展计划项目(编号:2012105)
关键词
二甲双胍
精神分裂症
肥胖
体重
糖脂代谢
Metformin
Schizophrenia
Obesity
Weight
Glucose and lipid metabolism
